The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Richard Funnell to join WVU Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

WVU Medicine announced Richard Funnell will join the WVU Cancer Institute as vice president of cancer services on May 21.

Funnell said his focus will be on changing the way cancer care is delivered by focusing on the patient experience and delivering value by lowering costs and improving access through more efficient operations across the network. He plans to grow the program’s capacity to serve a larger number of patients through fostering relationships across the state.

Funnell comes to WVU Medicine from the University of Pennsylvania Health System, Penn Medicine, where he served as chief administrative officer of the cancer service line and was responsible for the strategic direction and clinical operations of the Abramson Cancer Center and the Penn Cancer Network.

Prior to Penn Medicine, Funnell served as senior director of business development for oncology at Spectrum Health in Grand Rapids, MI, and as senior administrator for medical and pediatric oncology services at Roswell Park Cancer Institute.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account